Helping medtech companies form strategies and make critical decisions since 2007

 

Our medtech clients tell us that our comprehensive industry experience in medical devices is a significant asset in their strategy research.

That's why I've spent the past decade bringing together a group of medtech subject matter experts who help decrease decision risk, disrupt markets, drive share, and deliver results. Your company deserves to benefit from every opportunity it has for strategic growth.

-Maria Shepherd, President & CEO

 
 
 
 
 

Medical Devices

Our subject matter expert teams help clients respond to industry and market factors that create strategic uncertainty or opportunity for medical device companies.

Digital Healthcare

We help healthcare IT service providers, hospital IT, clinicians and patients steer through the complexities of the digital healthcare ecosystem as it intersects with medtech and diagnostics.

Diagnostics

We work with your team on innovation and strategy for  diagnostic technology in biomarkers, imaging technology, instrumentation, software, and reagents.

RECENT EVENTS

MedExecWomen 2023 - Growing Your Business, Yourself, and Your Leaders

May 16, 2023 | Boston

Maria Shepherd was a moderator at this year’s MedExecWomen for the panel “What Are The Implications Of Multi-Billion Dollar Acquisitions In Medtech?” featuring…

  • Heather Knight, EVP, Group President - Medical Products & Therapies, Baxter International

  • Jennifer Kozak, VP, Business Development, J&J Medtech

  • Rebecca Schechter, SVP and General Manager, Dragon Ambient Experience, Nuance Healthcare

 

CONTACT US

LOOKING FOR A PARTNER WITH KEY INSIGHTS INTO MEDICAL DEVICE TRENDS?

 

OUR LAST THREE PROJECTS WERE:

  • Medtech product strategy development: legacy product in a commodity space with potential for a meaningful digital health component

  • Medtech digital health price sensitivity conjoint study

  • M&A third party analysis of a medtech company with a digital health medical element

 

MEDTECH Blog Posts

Featured
Screenshot 2024-06-26 at 11.12.24 AM.png
Reveal Medtech Economic Value with Budgetary Impact Models

Communicating a robust economic strategy is paramount to device market success and often requires simplification into a budgetary impact model. Value analysis committees (VAC) hear presentations from medtech companies routinely and yours must stand out clearly.

deal table v2.001.jpeg
A Comparison of Global M&A Trends to Medtech

We all agree that 2023 was an inauspicious year for global medtech M&A. How are other, non Life Sciences (NLS) industries doing in Deal Terms? SRS Aquiom publishes great M&A research in the Life Sciences space for pharma, biotech and medtech. Their value proposition is that SRS Acquiom delivers the smartest way to run a deal™ with solutions that reduce the administrative burden throughout the entire deal lifecycle. Let’s compare global trends of NLS industries to Medtech.

Is 2024 the Year We See Medtech M&A Rally?
Is 2024 the Year We See Medtech M&A Rally?

2023 was a discouraging year for worldwide medtech M&A. According to McKinsey, in the life sciences sector, there were 745 transactions in 2023. Ninety-one percent had a value below $1 billion, and 54% fell below $100 million. Biotech and pharma deals were in the majority of deal volume—61% and 23%, respectively.